Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

Theodore S. Nowicki1, Ryan Akiyama1, Rong Rong Huang2, I. Peter Shintaku2, Xiaoyan Wang3,4, Paul C. Tumeh5,6,7, Arun Singh8, Bartosz Chmielowski9, Christopher Denny1,7, Noah Federman1,7,10, and Antoni Ribas6,7,8,9

Abstract

Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells, PD-1, thereby suppressing antitumor activity. Therapeutics blocking this interaction have shown promise in various cancers by restoring functional antitumor T-cell activity. We explored the degree of PD-L1, PD-1, and CD8 expression in a retrospective analysis of 29 clinical synovial sarcoma samples. Quantitative immunohistochemistry and multiplex immunofluorescence were used to determine relative quantification of CD8+ and PD-1+ T cells and PD-L1 expression within the intratumor area and the interface between the tumor and the surrounding nontumor tissue (i.e., invasive margin), and colocalization of these factors, respectively. PD-L1, PD-1, and CD8 cell densities in the tumor-invasive margins were significantly higher in the metastatic tumors than the primary tumors (P < 0.01), and PD-L1, PD-1, and CD8 cell densities were all significantly positively correlated with one another (P < 0.0001). PD-1 cell density in the tumor-invasive margin was significantly associated with worse progression-free survival. Multiplex immunofluorescence demonstrated coexpression of PD-1 and CD8 on lymphocytes within the invasive margin, as well as relative proximity between PD-1+ CD8 T cells and PD-L1+ tumor cells. Our results provide a preclinical rationale for screening of patients with synovial sarcoma for the colocalization of CD8, PD-1, and PD-L1, which may be a marker for response to PD-1 blockade therapy. Cancer Immunol Res; 5(2) February 2017

Introduction

Synovial sarcoma is an aggressive mesenchymal neoplasm with variable epithelial features, which accounts for 5% to 10% of all soft-tissue sarcomas (1). It chiefly affects older children and younger adults, and can occur at virtually any anatomic site. Clinical outcomes remain poor, with 5-year and 10-year survival rates of 60% and 50%, respectively (1, 2). Fifty percent of patients with synovial sarcoma patients develop metastases, primarily to the lungs or pleura, and have significantly worse clinical outcomes (1–3). Synovial sarcoma has a propensity for late recurrence and metastasis (occurring after 5 years), and 10 year minimum follow-up is generally recommended (1). Standard treatment for synovial sarcoma primarily consists of surgical resection, radiotherapy, and chemotherapy with alkylating agents, topoisomerase inhibitors, and anthracyclines. Although response rates of approximately 50% have been reported for these types of chemotherapy regimens, patients with refractory or recurrent/metastatic disease have few viable treatment options and none with proven improvements in survival (1, 2). The limitations in current treatment for synovial sarcoma make the development of new therapeutics a pressing concern, particularly for cases with metastatic disease.

The great majority (70%–80%) of synovial sarcomas express the cancer-testis antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1), which is encoded by the CTAG1B gene. This has allowed the successful clinical testing of a therapeutic approach targeting T cells specific for NY-ESO-1, with the use of adoptive cell therapy (ACT). ACT involves the generation of large quantities of CD8 T cells directed against specific tumor antigens. NY-ESO-1-specific T cells can be generated either by ex vivo expansion of endogenous, low-frequency NY-ESO-1–specific CD8 T cells, which are then infused into the patient (4, 5), or by ex vivo genetic modification of peripheral mononuclear blood cells, in which they are transduced with a T-cell receptor (TCR) directed against NY-ESO-1, expanded, and re-infused into the patient (6). Tumor vaccines have also been an effective means of stimulating patients’ dendritic cells to help generate T-cell activity directed against NY-ESO-1 (7). Clinical trials involving NY-ESO-1–directed ACT against synovial sarcoma have shown promise in achieving objective clinical responses in patients with metastatic or refractory disease (6). These therapies, although not FDA-approved, are therefore increasingly attractive treatment choices.
for metastatic and refractory synovial sarcoma and underscore the inherent immunogenicity of this malignancy and the need to further enhance therapies that exploit this immunogenicity.

The experience with NY-ESO-1 ACT in synovial sarcoma highlights that this is a tumor type that can be targeted effectively with immunotherapies. It is possible that pre-existing T cells in synovial sarcomas could be inhibited by an immune checkpoint, and releasing this inhibitory signal may result in antitumor activity. Programmed cell death 1 (PD-1) and its corresponding ligand PD-L1 have emerged as important immune checkpoints by which cancer cells evade the host immune response. Under normal conditions, PD-1 is expressed on activated CD8+ T cells, and its interaction with PD-L1 on host tissues leads to the inhibition of TCR signaling, limits the interactions between T cells and target cells, and ultimately leads to T-cell inactivation (8–11). PD-L1 expression is induced by localized inflammatory stimuli, such as IL7s, which are released by tumor-infiltrating lymphocytes (9). The PD-L1 induction process has been termed "adaptive immune resistance" (12) and represents a mechanism by which cancer cells protect themselves from immune-cell-mediated cell killing. This new paradigm led to the clinical development of antibodies blocking PD-1 or PD-L1, with which durable clinical responses are seen in a variety of malignancies, chiefly melanoma, non–small cell lung carcinoma, renal cell carcinoma, and diffuse large B-cell lymphoma (13–18). This has led to the exploration of the potential therapeutic utility of anti-PD-1/PD-L1 therapies in other malignancies as well. Previous work in other malignancies has explored how the presence of CD8 T cells in the tumor-invasive margin, along with concomitant PD-1 and PD-L1 expression within the tumor margin, predicts clinical response to PD-1 inhibitor therapy (19). Here, we report that PD-L1 expression is significantly increased in the invasive margin of metastatic synovial sarcoma tumors, and that this increased expression is correlated with significantly increased concentrations of PD-1 and CD8+ T lymphocytes. Our data provide preclinical rationale for the utility of PD-1/PD-L1 inhibition as a therapeutic option in this malignancy.

Methods

Patients and samples

A retrospective cohort of patients with synovial sarcoma who had undergone surgical resection at UCLA Ronald Reagan and UCLA Santa Monica hospitals and had appropriate tumor tissue for analyses was selected for analysis following approval by the University of California, Los Angeles Institutional Review Board (UCLA IRB) (#15-001483). All cases chosen had previously been diagnosed as synovial sarcoma by pathologist interpretation of tumor margin, concentric partitioning allowed the creation of a tumor perimeter of 400 mm, with 50% (200 μm) within the intratumor space, and 50% (200 μm) within the surrounding extra-tumor space. This area was defined as the invasive margin. Using the CytoNuclear module (cytoplasmic staining localization), algorithms were designed based on pattern recognition that were able to recognize positively stained NY-ESO-1, CD8, PD-1, or PD-L1 cells, and calculate the density (positive cells/mm²) and percent cellularity (% positive cells/all nucleated cells) within both niches, except for NY-ESO-1, which was only calculated within the intratumor niche. Density and percent cellularity values for NY-ESO-1, CD8, PD-1, and PD-L1 stains all positively correlated with each other (r values of 0.89, 0.98, 0.98, and 0.97, respectively, P < 0.0001 for each), and density measurements were used for subsequent analyses.

Multiplex immunohistochemistry staining

Multiplex immunohistochemistry analysis was conducted on eight metastatic samples shown to display significant expression of SSX-S18 fusion oncogene via fluorescence ISH. Patient age at biopsy, gender, prior chemotherapy and/or radiotherapy, progression-free survival (PFS), and overall survival (OS) were recorded for subsequent statistical analysis. PFS was defined as time from biopsy to time of subsequent surveillance CT scan of the chest/abdomen/pelvis demonstrating progression of disease, or censored/lost to follow-up. OS was defined as time from biopsy to time of death or censored/lost to follow-up. For both PFS and OS data, were followed out to 60 months, beyond which they were censored. Formalin-fixed paraffin-embedded tissue blocks were obtained from the UCLA Translational Pathology Core Laboratory, and 5-μm-thick serial sections were generated for subsequent immunohistochemistry (IHC) and multiplex immunofluorescence.
expression of CD8, PD-1, and PD-L1. Serial sections from patient tumor samples were deparaffinized and rehydrated with a series of graded ethanols to deionized water. Antigen retrieval was performed in Tris-EDTA at pH 9, and slides were cooked at high pressure at 120°C for 15 minutes. Slides were then serially stained with anti–PD-1 clone NAT105 (1/1,500; Cell Marque), anti–PD-L1 clone SP142 (1/4,000; SpringBio), anti–CD8 clone C8/144B (1/5,000, DAKO), or anti–TLE1 clone ab183742 (1/2,000; Abcam), which served as a specific nuclear marker for synovial sarcoma tissue. Horseradish peroxidase–conjugated secondary labeling was performed using SuperPicture Polymer detection system. Signal for individual antibody complexes was labeled and visualized with FITC, Cy3, Cy5, and Cy3.5 tyramide signal amplification kits (PerkinElmer). Individual primary/secondary antibody complexes were stripped via microwave treatment, and the process was repeated for each subsequent antibody labeling for a different antigen and fluorophore. Nuclei were visualized with Prolong Gold Antifade Mounting Medium (Invitrogen), and slides were then coverslipped for imaging. Stained slides were imaged using excitation and emission spectra for each individual fluorophore, and overlaid composite images were generated using the Vectra Intelligent Slide Analysis system on an Olympus BX-51WI microscope (PerkinElmer). Fields at 200X magnification were chosen which corresponded with areas of the invasive margin which were noted to have high expression of PD-L1, PD-1, and CD8 in the brightfield IHC experiments.

Statistical analysis

Descriptive statistics were calculated and presented in tables. For the comparison of the characteristics of primary patients and metastatic patients, unpaired Student t test was used for age, and the Fisher exact test was used for gender, prior chemotherapy, and prior radiotherapy. The OS probability and the PFS probability were estimated and presented by Kaplan–Meier survival curves. The log-rank test was used for testing the OS and the PFS between primary patients and metastatic patients, respectively. Differences between metastatic and primary tumors’ PD-L1, PD-1, and CD8 brightfield IHC cell densities in intratumor and invasive margin niches were compared using the Wilcoxon rank-sum test, and correlations between PD-L1, PD-1, and CD8 cell densities were compared using Spearman rank correlation. For all subjects and the subsets of metastatic and primary tumors, univariate Cox proportional hazard regression was used to correlate OS/PFS with log2-transformed PD-L1, PD-1, and CD8 cell densities. All statistical tests were two-sided. P values less than 0.05 were considered statistically significant. Prism v6.0 software (GraphPad) and SAS Version 9.4 (SAS Institute, Inc.) were used for statistical analysis.

Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (N = 29) patients (%)</th>
<th>Primary (n = 12) patients (%)</th>
<th>Metastatic (n = 17) patients (%)</th>
<th>Significance between primary and metastatic (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>19 (65.6)</td>
<td>7 (58.3)</td>
<td>12 (70.6)</td>
<td>0.69</td>
</tr>
<tr>
<td>Female</td>
<td>10 (34.4)</td>
<td>5 (41.7)</td>
<td>5 (29.4)</td>
<td></td>
</tr>
<tr>
<td>Mean age at surgery, years</td>
<td>37.9 (25.0–48.0)</td>
<td>35.3 (24.5–46.0)</td>
<td>39.8 (28.0–49.0)</td>
<td>0.47</td>
</tr>
<tr>
<td>Prior chemotherapy</td>
<td>20 (69.0)</td>
<td>4 (33.3)</td>
<td>16 (94.1)</td>
<td>0.001</td>
</tr>
<tr>
<td>Prior radiotherapy</td>
<td>13 (44.8)</td>
<td>3 (25.0)</td>
<td>10 (5)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Results

Patient characteristics and clinical outcomes

Tumor tissues from biopsies and surgical resections from 29 patients with synovial sarcoma (12 primary lesions, 17 metastatic lesions) were selected for analysis. All metastatic samples were derived from lung metastases. Table 1 and Fig. 1A and B summarize data regarding the demographics, prior treatment, and PFS or OS between the two groups. At 60 months, the OS probabilities were 59.9% for all subjects, 78.6% for the patients with primary sarcoma, and 44.0% for the patients with metastatic sarcoma, respectively. The 60-month PFS probabilities were 53.3% for all subjects, 81.8% for the patients with primary sarcoma, and 34.3% for the patients with metastatic sarcoma, respectively. The metastatic disease population had a significantly higher incidence of prior chemotherapy than did the primary disease population.

PD-1 expression in tumor-invasive margins correlated with worse PFS survival

Biopsies were stained by IHC and analyzed using quantitative digital pathology via the Indica Labs Halo platform as described above (Fig. 2). PD-1 cell density in the invasive margin niche was significantly associated with worse PFS for all patients. The HR for log2-transformed PD-1 density in the invasive margin was 1.62 based on univariate Cox proportional hazard regression analysis (P = 0.006). CD8 and PD-L1 invasive margin cell densities approached, but did not achieve, statistically significant association with worse PFS, with HR values of 1.24 (P = 0.082) and 1.21 (P = 0.071), respectively. The association between CD8, PD-1, or PD-L1 intratumor cell densities and PFS was not statistically significant, nor was the association between CD8, PD-1, or PD-L1 invasive margin or intratumor cell densities and OS. No other associations were significant between CD8, PD-1, and PD-L1 densities in the invasive margin or the intratumor niches with patient age, gender, or prior treatment.

Metastatic synovial sarcomas had increased PD-L1, PD-1, and CD8 in invasive margins

Using the Halo image analysis platform to quantify cell densities within intratumor and invasive margin niches (data summarized in Table 2), we determined that PD-L1, PD-1, and CD8 cell densities in the tumor-invasive margins were all significantly higher in the metastatic tumors compared with the primary tumors (Fig. 3A). Furthermore, PD-L1, PD-1, and CD8 cell densities were all significantly positively correlated with one other within the invasive margin niche (Fig. 3B). Within the invasive margin niche, we observed positive correlation between cell density values for PD-1 with CD8 (r = 0.76, P < 0.0001), PD-L1 with CD8 (r = 0.71, P < 0.0001), and PD-L1 with
PD-1 \( (r = 0.67, P < 0.0001) \). Intratumor PD-L1 density was also significantly higher \( (P < 0.01) \) in the metastatic tumors compared with the primary tumors (Fig. 3C). Although the CD8 and PD-1 cell densities trended higher in the intratumor niche of the metastatic tumors as compared with the primary tumors, the differences did not achieve statistical significance \( (P = 0.11 \text{ and } P = 0.08, \text{ respectively}) \). However, we still observed a similarly striking positive correlation between PD-1 with CD8 \( (r = 0.72, P < 0.0001) \), PD-L1 with CD8 \( (r = 0.58, P < 0.01) \), and PD-L1 with PD-1 \( (r = 0.63, P < 0.001) \) cell densities within the intratumor niche.

Figure 1. Kaplan-Meier survival curves comparing PFS (A) and OS (B) between patients with primary and metastatic disease to 60 months.
niche (Fig. 3D). NY-ESO-1 density was not correlated with CD8, PD-1, or PD-L1 densities in either the invasive margin or intra-tumor niches (data not shown).

Multiplex immuno-fluorescence was used to confirm that the increased PD-L1 and PD-1 expressions in the tumor-invasive margins were present on the synovial sarcoma tumor cells and the CD8 T cells, respectively. This technique enables the serial fluorescent labeling of multiple proteins within a single-tissue slide. Coexpression of PD-1 and CD8 was demonstrated on lymphocytes present within the tumor-invasive margins, as well as qualitative proximity between PD-1$^+$ cells and PD-L1$^+$ tumor cells. PD-L1 was expressed on tumor cells, which were distinguished by the presence of synovial sarcoma–specific TLE1 nuclear staining (Fig. 4).

**Figure 2.** Overview of quantitative IHC image analysis. Images represent the same fields of view of serial sections from tumor tissue. Tumor area (yellow line) is delineated via cell morphology and the presence of synovial sarcoma tumor markers in corresponding serial sections (Bcl-2, CD99, EMA, or NY-ESO-1). Once the tumor border has been established, a perimeter of 400-μm thickness is established via concentric partitioning, consisting of 50% intratumor space and 50% extra-tumor space. This perimeter (the area between the two green lines) is defined as the tumor-invasive margin. CD8 (top row), PD-1 (middle row), and PD-L1 (bottom row) cell density analyses are then performed in serial sections for both the intratumor and the invasive margin niches, with cell density reported as number of positive cells/mm$^2$. Cells marked yellow are scored as positive, whereas cells marked blue are scored as negative. Magnification, ×80.

**Table 2. Summary of cell density measurements.**

<table>
<thead>
<tr>
<th>Cell density</th>
<th>Total ($N=29$)</th>
<th>Primary ($n=12$)</th>
<th>Metastatic ($n=17$)</th>
<th>Significance between primary and metastatic (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean, cells/mm$^2$; median, cells/mm$^2$ (range)</td>
<td>Mean, cells/mm$^2$; median, cells/mm$^2$ (range)</td>
<td>Mean, cells/mm$^2$; median, cells/mm$^2$ (range)</td>
<td></td>
</tr>
<tr>
<td>CD8 (invasive margin)</td>
<td>107.9; 44.1 (0–750)</td>
<td>73.0; 9.9 (0–750)</td>
<td>132.5; 100.3 (23.1–357.1)</td>
<td>0.0003</td>
</tr>
<tr>
<td>PD-1 (invasive margin)</td>
<td>82.5; 48.9 (1.8–361.6)</td>
<td>416; 8.9 (1.8–293.2)</td>
<td>111.5; 83.4 (16.2–361.6)</td>
<td>0.002</td>
</tr>
<tr>
<td>PD-L1 (invasive margin)</td>
<td>174.2; 115.9 (0–1035)</td>
<td>80.0; 5.7 (0–862.8)</td>
<td>240.6; 194.5 (15.8–1035)</td>
<td>0.0003</td>
</tr>
<tr>
<td>CD8 (intratumor)</td>
<td>53.4; 15.0 (1.3–414.3)</td>
<td>26.2; 8.1 (2.2–204.7)</td>
<td>72.6; 36.9 (13.4–414.3)</td>
<td>0.11</td>
</tr>
<tr>
<td>PD-1 (intratumor)</td>
<td>36.9; 11.1 (1.1–309)</td>
<td>24.8; 5.3 (1.1–182.9)</td>
<td>45.5; 20.9 (15.3–309)</td>
<td>0.08</td>
</tr>
<tr>
<td>PD-L1 (intratumor)</td>
<td>173.3; 243.5 (1.5–1940)</td>
<td>171.3; 5.5 (1.5–1940)</td>
<td>174.7; 53.7 (1.6–1177)</td>
<td>0.006</td>
</tr>
<tr>
<td>NY-ESO-1</td>
<td>5,024; 5,334 (566–9,170)</td>
<td>4,682; 5,050 (566–8,983)</td>
<td>5,265; 5,920 (946–9,170)</td>
<td>0.44</td>
</tr>
</tbody>
</table>
Given the grim prognosis and lack of efficacious treatment options for metastatic synovial sarcoma, the exploration of novel therapeutics for this malignancy is of ample interest. The recent widespread success of T-cell–based immunotherapy for multiple other cancers, specifically via PD-1/PD-L1 inhibition, has

Figure 3.
A, Relative CD8, PD-L1, and PD-1 cell densities in the invasive margins of all samples of synovial sarcoma. PD-L1, PD-1, and CD8 cell densities were all significantly higher in the invasive margins of metastatic compared with primary tumors (**, *P* < 0.01; ‼, *P* < 0.0001). Error bars represent SDs. B, Spearman correlation plots demonstrating that CD8, PD-L1, and PD-1 cell densities all positively correlate with one another within both the invasive margins. C, Relative CD8, PD-L1, and PD-1 cell densities in the intratumor margins of all samples of synovial sarcoma. PD-L1 cell densities were significantly higher in the intratumor niche of metastatic compared with primary tumors (**, *P* < 0.01). D, Spearman correlation plots demonstrating that CD8, PD-L1, and PD-1 cell densities all positively correlate with one another within the intratumor niches.

**Discussion**

Given the grim prognosis and lack of efficacious treatment options for metastatic synovial sarcoma, the exploration of novel therapeutics is of ample interest. The recent widespread success of T-cell–based immunotherapy for multiple other cancers, specifically via PD-1/PD-L1 inhibition, has
generated hope that these techniques could be applied to synovial sarcomas, as well as other soft-tissue malignancies.

Our data show that PD-L1 is expressed in synovial sarcoma, predominantly in lung metastases. This increased PD-L1 expression is proximally associated with increased concentrations of CD8 TILs expressing PD-1 in the tumor-invasive margin. It is known that PD-1 can be expressed on numerous cell types in addition to CD8 T cells, including B cells (20); PD-L1 expression has also been reported in dendritic cells, macrophages, plasma cells, and B cells (20–23). It is possible that the minority of cells observed expressing PD-L1 without TLE1, or PD-1 without CD8, may represent associated expression with any of these other cell types.

Our data showed that increased expressions of PD-L1, PD-1, and CD8 are directly correlated with one another. In several cases, PD-L1 expression was substantially higher than the associated PD-1 and CD8 expression densities (Fig. 3B and D). As PD-L1 can be either constitutively expressed or induced via localized inflammatory stimuli within the tumor microenvironment, such as IFNs (24–26), it may be that a subset of tumors have preexisting constitutive expression of PD-L1 in addition to induction by inflammatory stimuli. Alternatively, they may represent a subset of synovial sarcomas that are more sensitive to inflammatory stimuli, resulting in a more dramatic PD-L1 induction. Further studies at the genomic and transcriptomic levels are needed to fully elucidate the significance of such tumors as they pertain to potential responsiveness inflammatory stimuli and PD-1/PD-L1 inhibition.

These expression patterns of PD-L1 in close proximity to PD-1–positive CD8 TILs at the invasive margin are analogous to what our group has previously reported with melanoma (19), and what others have reported in other malignancies as well, including other sarcoma subtypes, such as gastrointestinal stromal tumors, osteosarcoma, and chondrosarcoma (25, 27–29). D’Angelo and colleagues previously reported a study of PD-L1, PD-1, and CD8 expression patterns in a large number of sarcoma subtypes (29). Although their study reported no significant expression of PD-L1, PD-1, or CD8 in synovial sarcoma, they only studied a very small number of samples from that malignancy (n = 5), their study did not distinguish between primary and metastatic tumor samples, and it did not specifically focus in the area of the tumor with most interest, the invasive margin. In our study, the higher incidence of prior chemotherapy was not associated with different PD-L1, PD-1, or CD8 expression. However, we found that PD-1 density in the tumor-invasive margin was significantly associated with lower PFS, and CD8 and PD-L1 densities in the invasive margin also approached significance in this association, as well. This phenomenon has been studied in multiple cancer subtypes, with PD-1 or PD-L1 expression levels being associated with either favorable or unfavorable impacts on PFS or OS, depending on the cancer type studied (30–33). Further prospective studies are needed to further explore and validate these associations, as well as further study how such expression patterns would predict responsiveness to PD-1/PD-L1 inhibitor therapy.

Given that our prior experience with melanoma demonstrated that the presence of CD8 TILs at the tumor-invasive margin (along
with concomitant proximal PD-1 and PD-L1 induction) predicted clinical response to PD-1 inhibition, it is reasonable to extrapolate that this pattern might predict clinical response to PD-1 inhibition in other tumor types as well. SARC 028 is an ongoing phase II clinical trial exploring the use of the pembrolizumab (an antibody to PD-1) in multiple sarcoma subtypes, including synovial sarcoma (34). It would be of great interest to correlate any clinical responses of synovial sarcoma patients with pre-existing CD8 infiltration and concomitant proximal PD-1 and PD-L1 expression. We have found no correlation between NY-ESO-1 density and CD8, PD-1, or PD-L1 density in either the invasive margin or intratumor niches. It may be that NY-ESO-1 is not a sufficiently strong antigen to provoke a significant CD8 T-cell response in itself. There may also be fundamental differences in certain subtypes of synovial sarcoma which render them more sensitive or resistant to a CD8 T-cell response. Spranger and colleagues previously reported an inverse relationship between melanoma-intrinsic β-catenin signaling and intratumoral T-cell infiltration (35, 36). Given that β-catenin induction has been documented in synovial sarcoma cases with particularly poor prognoses (37, 38), it may be that this or other factors may contribute to the baseline TIL activity which might be present in a given tumor. Further studies at the genomic and transcriptomic levels may reveal baseline tumor mutations, as well as novel tumor antigens or neoepitopes resulting from nonsynonymous mutations, which collectively are responsible for the immunogenicity of certain subsets of synovial sarcoma. However, a lack of pre-existing CD8, PD-1, or PD-L1 induction might not preclude the use of PD-1 inhibitors in synovial sarcoma, due to the high exploitability of this malignancy for adoptive cell therapy directed at NY-ESO-1. Patients without a pre-existing CD8 infiltrate could be provided one via adoptive cell therapy, which could then be combined with anti-PD-1 therapy to perpetuate the inherently limited duration of initially robust antitumor activity of this therapeutic modality. Alternatively, if endogenous T cells are already present in a given tumor, but their activation is blocked by PD-1/PD-L1 interactions, they may simply need to be unleashed in situ, as opposed to requiring the ex vivo manipulation of T cells.

Our study has several limitations. First, as our study was based on a retrospective analysis of synovial sarcoma tumors, we could not define a critical threshold of PD-L1, PD-1, or CD8 cell density required for a therapeutic response to PD-1/PD-L1 blockade. Additional studies in the future might identify expression thresholds linked to improved treatment responses. Furthermore, although the Aperio scans of the brightfield IHC slides enabled whole slide visualization with the ability to zoom in gradually up to 200x, the Vectra imaging system used for multiplex immunofluorescence imaging only permitted direct visualization using 200x total magnification. As such, we were unable to obtain whole slide images and subject them to the same whole slide analysis with the Indica Labs Halo platform that was used for the brightfield IHC. Finally, our analysis methods utilized serial slides derived from primary tumor resection or wedge resections of lung metastases of synovial sarcoma tumors instead of tissue microarrays, which we felt would not allow for accurate visualization of the tumor-invasive margin with the surrounding normal tissue. Although whole tumor or wedge resection analysis allows for a more complete representation of PD-L1, PD-1, or CD8 density variations within the tumor-invasive margin, we recognize that prospective wedge resection and subsequent analysis of lung metastases to determine likelihood of treatment success with PD-1/PD-L1 inhibitors may not be technically feasible in every patient.

In summary, our results provide preclinical rationale for screening of patients with synovial sarcoma for this pattern of PD-L1/PD-1 induction in the setting of CD8 T-cell infiltration, as well as possible treatment of patients with synovial sarcoma with PD-1/PD-L1 inhibitors, especially in patients with metastatic disease, who often have few treatment options. Patients who do not have a pre-existing CD8 infiltrate could potentially be given one via adoptive cell therapy, which could then be combined with PD-1/PD-L1 inhibition for enhanced therapeutic response.

Disclosure of Potential Conflicts of Interest
B. Chmielowski reports receiving honoraria from the Speakers Bureau of Genentech and is a consultant/advisory board member for BMS and Merck. No potential conflicts of interest were disclosed by the other authors.

Disclaimer
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the NIH, Stand Up To Cancer, or the Parker Institute for Cancer Immunotherapy.

Authors' Contributions
Conception and design: T.S. Nowicki, C. Denny, N. Federman, A. Ribas
Development of methodology: T.S. Nowicki, R.R. Huang, I.P. Shintaku, P.C. Tumeh, A. Ribas
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T.S. Nowicki, R. Akiyama, R.R. Huang, I.P. Shintaku, P.C. Tumeh, A. Singh, B. Chmielowski, C. Denny, N. Federman, A. Ribas
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T.S. Nowicki, R. Akiyama, X. Wang, P.C. Tumeh, B. Chmielowski, A. Ribas
Writing, review, and/or revision of the manuscript: T.S. Nowicki, X. Wang, P.C. Tumeh, A. Singh, B. Chmielowski, N. Federman, A. Ribas
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.R. Huang, A. Ribas
Study supervision: T.S. Nowicki, C. Denny, A. Ribas

Acknowledgments
We gratefully acknowledge the staff at the UCLA Translational Pathology Core Laboratories for technical assistance with tissue sample processing and digital slide image acquisition. We also gratefully acknowledge Philip Sanchez and Mariam Vanestyan for their technical assistance and helpful conversations regarding the multiplex immunofluorescence image acquisition.

Grant Support
This work was funded by NIH grants R35 CA197633 and P01 CA168585, the Parker Institute for Cancer Immunotherapy, the Dr. Robert Vigen Memorial Fund, the Ressler Family Fund, the Ruby Family Fund, the Wesley Coyle Memorial Fund, and the Garcia-Cortini Family Fund (to A. Ribas). A. Ribas was supported by a Stand Up To Cancer – Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant [S122-CA-ACR-DT1012]. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 30, 2016; revised November 1, 2016; accepted November 30, 2016; published OnlineFirst December 30, 2016.
References
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

Theodore S. Nowicki, Ryan Akiyama, Rong Rong Huang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-16-0148

Cited articles
This article cites 38 articles, 8 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/5/2/118.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/5/2/118.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerimmunolres.aacrjournals.org/content/5/2/118.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.